Dupilumab for Eosinophilic Esophagitis May Lower Pediatric Asthma Risk
Young children treated with dupilumab (Dupixent) for eosinophilic esophagitis (EoE) were less likely to develop asthma later.
Young children treated with dupilumab (Dupixent) for eosinophilic esophagitis (EoE) were less likely to develop asthma later.
Young children treated with dupilumab (Dupixent) for eosinophilic esophagitis (EoE) were less likely to develop asthma later.
Read MoreApproximately 40% of insurance requests for pediatric asthma biologic therapies are denied, with approvals taking more than a month on average.
Read MoreBiologics including Dupilumab and anti-IL-5 agents were associated with a lower probability of pneumonia within the study.
Read MoreThe VESTIGE study is the first study to show a reduction in lung mucus buildup in asthma patients treated with dupilumab/Dupixent.
Read MoreThe FDA has approved Dupixent for adults with inadequately controlled COPD and an eosinophilic phenotype.
Read MoreThe FDA has approved Dupixent as an add-on maintenance treatment for adolescents aged 12-17 with chronic rhinosinusitis with nasal polyps, expanding its original approval for adults in 2019.
Read MoreThe European Commission has approved Dupixent as an add-on treatment for adults with uncontrolled COPD.
Read MoreA new ACAAI position paper concludes that live vaccines are generally safe for patients on dupilumab but emphasizes the importance of shared decision-making.
Read MoreTwo practice parameters from the Joint Task Force for Practice Parameters offer evidence-based recommendations for the diagnosis and management of anaphylaxis and atopic dermatitis in pediatric and adult patients.
Read MoreCombining immunotherapy with dupilumab boosted lung cancer patients’ immune systems, with one out of the six experiencing significant tumor reduction, according to findings published in Nature.
Read MoreIn an early parallel study in humans with non-small cell lung cancer, combining immunotherapy with dupilumab boosted patients’ immune systems, with one out of the six experiencing significant tumor reduction.
Read MoreThe second Dupixent investigational phase 3 COPD trial has shown that Dupixent reduced exacerbations by 34%, confirming positive published results from the phase 3 BOREAS trial.
Read MoreSevere asthma patients account for as much as 60% of all asthma healthcare costs, and proper management of severe disease is essential.
Read MoreThe monoclonal antibody is the first biologic shown to improve clinical outcomes in COPD, according to investigators.
Read MoreIn patients with eosinophilic sinusitis and comorbid bronchial asthma, sinusitis treatment with dupilumab may ease asthma symptoms.
Read MoreThe National Institutes of Health has launched a clinical trial testing whether a monoclonal antibody, dupilumab, can reduce asthma attacks and improve lung function and asthma symptoms in children with poorly controlled allergic asthma who live in low-income urban neighborhoods.
Read MoreThe National Institutes of Health has launched a clinical trial testing whether a monoclonal antibody, dupilumab, can reduce asthma attacks and improve lung function and asthma symptoms in children with poorly controlled allergic asthma who live in low-income urban neighborhoods.
Read MoreA new study looked at functional respiratory imaging to assess the effects of the asthma biologic dupilumab on lung function in asthma patients.
Read MoreThe FDA has approved dupilumab (Dupixent, Regeneron) as an add-on maintenance treatment of patients aged 6 to 11 years with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma.
Read MoreChildren age 6-11 with uncontrolled, moderate-to-severe asthma and a type 2 inflammatory asthma phenotype who received add-on dupilumab (Dupixent, Regeneron) had significant improvements in lung function at week 12 of therapy, according to research presented at Chest 2021.
Read MoreA clinical trial of dupilumab (Dupixent) showed that the monoclonal antibody significantly reduced exacerbations in children ages 6-11 with uncontrolled moderate-to-severe asthma, compared to placebo.
Read MoreThe FDA will review an sBLA for Dupixent (dupilumab) as an add-on treatment for children aged 6 to 11 years with uncontrolled moderate-to-severe asthma.
Read MoreFDA approved a 300 mg single-dose pre-filled pen for Dupixent (dupilumab) to treat atopic dermatitis, asthma and chronic rhinosinusitis with nasal polyposis (CRSwNP).
Read MoreIn adults with severe chronic rhinosinusitus with nasal polyps (CRSwNP), the monoclonal antibody dupilumab is effective for shrinking the polyps, improving symptoms, and reducing the need for systemic corticosteroids and...
Read More